Analysts Offer Predictions for Vor Biopharma Q3 Earnings

Key Points

• HC Wainwright has reduced its Q3 2025 earnings per share (EPS) estimate for Vor Biopharma to ($0.22), down from a prior forecast of ($0.18), while maintaining a "Buy" rating with a price target of $3.00.
• Multiple brokerages have downgraded their ratings on Vor Biopharma, with several moving from "strong-buy" to "hold," reflecting a cautious outlook among analysts.
• Vor Biopharma's shares have shown significant movement, with a recent trading price of $2.14, indicating an 8.1% increase, amidst a broad presence of institutional investors owning 97.29% of the stock.

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Equities researchers at HC Wainwright lowered their Q3 2025 earnings per share estimates for shares of Vor Biopharma in a research report issued on Thursday, August 14th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.22) for the quarter, down from their prior estimate of ($0.18). HC Wainwright currently has a "Buy" rating and a $3.00 price objective on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma's Q4 2025 earnings at ($0.20) EPS, Q1 2026 earnings at ($0.20) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.78) EPS and FY2027 earnings at ($0.73) EPS.

Several other research firms also recently commented on VOR. JMP Securities restated a "market perform" rating and set a $6.00 target price on shares of Vor Biopharma in a research report on Friday, May 9th. Wedbush restated an "outperform" rating on shares of Vor Biopharma in a research report on Thursday, June 26th. Baird R W downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Jones Trading downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Finally, Citizens Jmp downgraded Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 9th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $6.07.

Vor Biopharma Stock Performance

Shares of VOR stock remained flat at $2.17 during mid-day trading on Monday. The company's stock had a trading volume of 2,855,277 shares, compared to its average volume of 7,882,951. The company has a 50 day moving average of $1.78 and a 200 day moving average of $1.07. Vor Biopharma has a 52 week low of $0.13 and a 52 week high of $3.29. The company has a market capitalization of $274.90 million, a price-to-earnings ratio of -1.32 and a beta of 2.06.

Hedge Funds Weigh In On Vor Biopharma

Several institutional investors have recently bought and sold shares of the business. Two Sigma Investments LP raised its position in Vor Biopharma by 18.9% in the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after purchasing an additional 25,930 shares during the last quarter. Money Concepts Capital Corp increased its stake in shares of Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares during the period. XTX Topco Ltd acquired a new stake in shares of Vor Biopharma in the 2nd quarter valued at $66,000. Northern Trust Corp increased its stake in shares of Vor Biopharma by 39.0% in the 4th quarter. Northern Trust Corp now owns 157,617 shares of the company's stock valued at $175,000 after buying an additional 44,252 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in shares of Vor Biopharma by 218.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after buying an additional 58,247 shares during the period. Institutional investors own 97.29% of the company's stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.